Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

838.70INR
6:29am EDT
Change (% chg)

Rs-2.45 (-0.29%)
Prev Close
Rs841.15
Open
Rs842.00
Day's High
Rs849.00
Day's Low
Rs835.00
Volume
1,622,232
Avg. Vol
1,759,155
52-wk High
Rs891.50
52-wk Low
Rs582.00

Latest Key Developments (Source: Significant Developments)

Aurobindo Pharma receives USFDA approval for Linezolid injection
Monday, 8 Aug 2016 12:33am EDT 

Aurobindo Pharma Ltd : Aurobindo Pharma receives USFDA approval for Linezolid injection . Product is expected to be launched by Q2 FY 2016-17 .  Full Article

Aurobindo Pharma gets USFDA approval for rosuvastatin calcium tablets
Wednesday, 20 Jul 2016 12:19am EDT 

Aurobindo Pharma Ltd : Aurobindo Pharma receives usfda approval for rosuvastatin calcium tablets .  Full Article

Aurobindo Pharma gets USFDA approval for hydromorphone hydrochloride tablets
Tuesday, 17 May 2016 01:50am EDT 

Aurobindo Pharma Ltd : Aurobindo Pharma receives usfda approval for hydromorphone hydrochloride tablets .  Full Article

Aurobindo Pharma gets US FDA approval for bupivacaine hydrochloride injection
Monday, 16 May 2016 12:20am EDT 

Aurobindo Pharma Ltd : Gets US FDA approval for bupivacaine hydrochloride injection .  Full Article

Aurobindo Pharma gets USFDA approval for Zolmitriptan tablets
Friday, 13 May 2016 05:03am EDT 

Aurobindo Pharma Ltd : Receives USFDA approval for Zolmitriptan tablets; product expected to be launched in Q2 FY 2016-17 .  Full Article

Aurobindo Pharma gets USFDA approval for Fenofibrate tablets
Friday, 6 May 2016 01:28am EDT 

Aurobindo Pharma Ltd : Aurobindo Pharma receives USFDA approval for Fenofibrate tablets; product is expected to be launched in Q1 FY 2016-17 .  Full Article

Aurobindo Pharma Ltd receives USFDA Approval for Dexmedetomidine Hydrochloride Injection
Friday, 18 Mar 2016 01:10am EDT 

Aurobindo Pharma Ltd:Says that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride Injection, 200 mcg (base)/2 mL (100 mcg (base)/mL) single-dose vials.  Full Article

Aurobindo Pharma Ltd receives USFDA Approval for Ibandronate Sodium Tablets
Tuesday, 15 Mar 2016 12:35am EDT 

Aurobindo Pharma Ltd:Says that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ibandronate Sodium Tablets, 150 mg.Says this product is expected to be launched in Q1 FY16-17.Approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva Tablets of Hoffman-La Roche Inc.  Full Article

Aurobindo Pharma Ltd receives USFDA approval for Celecoxib capsules
Tuesday, 2 Feb 2016 01:18am EST 

Aurobindo Pharma Ltd:Says that it has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.Says this product is expected to be launched in Q4 FY15-16.  Full Article

Aurobindo Pharma Ltd receives USFDA Approval for Voriconazole tablet
Wednesday, 27 Jan 2016 01:33am EST 

Aurobindo Pharma Ltd:Says that it has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Voriconazole Tablets, 50 mg and 200 mg.Says this product is expected to be launched in Q4 FY15-16.Says approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) VFEND Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).  Full Article

BRIEF-Aurobindo Pharma gets USFDA tentative approval for Dolutegravir

* Aurobindo Pharma receives USFDA tentative approval for Dolutegravir, allowing the product to be launched in the PEPFAR market Source text: (http://bit.ly/2cTnfIs) Further company coverage: (Bengaluru newsroom)